DaVita (DVA)
(Real Time Quote from BATS)
$162.34 USD
-1.66 (-1.01%)
Updated Sep 23, 2024 02:06 PM ET
1-Strong Buy of 5 1
A Value C Growth C Momentum B VGM
DaVita HealthCare (DVA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$155.86 | $175.00 | $145.00 | -4.96% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for DaVita HealthCare comes to $155.86. The forecasts range from a low of $145.00 to a high of $175.00. The average price target represents a decline of 4.96% from the last closing price of $164.00.
Analyst Price Targets (7 )
Broker Rating
DaVita HealthCare currently has an average brokerage recommendation (ABR) of 2.88 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.86 a month ago based on seven recommendations.
Of the eight recommendations deriving the current ABR, one is Strong Buy, representing 12.5% of all recommendations. A month ago, Strong Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 5 | 5 | 5 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.88 | 2.86 | 2.86 | 2.86 | 2.86 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/19/2024 | Not Identified | Not Identified | Hold | Hold |
8/20/2024 | Truist Securities | David S Macdonald | Hold | Hold |
8/8/2024 | UBS | Aj Rice | Strong Buy | Strong Buy |
8/7/2024 | Not Identified | Not Identified | Hold | Hold |
8/7/2024 | Cowen & Co. | Ryan Langston | Hold | Hold |
3/27/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.88 |
ABR (Last week) | 2.86 |
# of Recs in ABR | 8 |
Average Target Price | $155.86 |
LT Growth Rate | 17.50% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 46 of 253 |
Current Quarter EPS Est: | 2.76 |
DVA FAQs
DaVita Inc. (DVA) currently has an average brokerage recommendation (ABR) of 2.88 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 8 brokerage firms.
The average price target for DaVita Inc. (DVA) is $155.86. The current on short-term price targets is based on 3 reports.
The forecasts for DaVita Inc. (DVA) range from a low of $145 to a high of $175. The average price target represents a decline of $4.96 from the last closing price of $164.00.
The current DOWNSIDE for DaVita Inc. (DVA) is 4.96%
Based on short-term price targets offered by seven analysts, the average price target for DaVita HealthCare comes to $155.86. The forecasts range from a low of $145.00 to a high of $175.00. The average price target represents a decline of 4.96% from the last closing price of $164.00.